Appendix 4G and Corporate Governance Statement
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
CLINUVEL delivering on a long-term strategy with increase in annual revenues, profit
Melbourne, Australia, 29 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Dividend/Distribution – CUV
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
Appendix 4E & Annual Report
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read More
Notification regarding unquoted securities
CLINUVEL today released a notification regarding unquoted securities.
Read More
Notification of cessation of securities
CLINUVEL today released a notification regarding cessation of securities.
Read More
Change of Director’s Interest Notice
CLINUVEL today released a notification regarding a change of Director’s interest.
Read More
Investor Presentation - NYC Nasdaq Event
CLINUVEL hosted a Rendez-Vous evening event at the Nasdaq in New York...
Read More
First stroke patient treated with PRÉNUMBRA® Instant
CLINUVEL has started its second stroke trial (CUV803) with the first patient...
Read More
Statement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Commercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read More
Relief from Quarterly Reporting
Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Proposed issue of Securities
Melbourne, Australia, 28 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More